Executive Wealth Management LLC Has $86,000 Stake in Bristol-Myers Squibb Co (NYSE:BMY)

Share on StockTwits

Executive Wealth Management LLC trimmed its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 14.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,895 shares of the biopharmaceutical company’s stock after selling 325 shares during the period. Executive Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $86,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Lodestar Investment Counsel LLC IL increased its holdings in shares of Bristol-Myers Squibb by 5.2% in the second quarter. Lodestar Investment Counsel LLC IL now owns 113,720 shares of the biopharmaceutical company’s stock valued at $5,157,000 after purchasing an additional 5,579 shares during the last quarter. Perella Weinberg Partners Capital Management LP increased its holdings in shares of Bristol-Myers Squibb by 10.9% in the first quarter. Perella Weinberg Partners Capital Management LP now owns 19,431 shares of the biopharmaceutical company’s stock valued at $99,000 after purchasing an additional 1,905 shares during the last quarter. Stephens Inc. AR increased its holdings in shares of Bristol-Myers Squibb by 30.7% in the first quarter. Stephens Inc. AR now owns 216,532 shares of the biopharmaceutical company’s stock valued at $10,331,000 after purchasing an additional 50,798 shares during the last quarter. Nachman Norwood & Parrott Inc increased its holdings in shares of Bristol-Myers Squibb by 3.5% in the second quarter. Nachman Norwood & Parrott Inc now owns 50,388 shares of the biopharmaceutical company’s stock valued at $2,285,000 after purchasing an additional 1,687 shares during the last quarter. Finally, Edge Wealth Management LLC increased its holdings in shares of Bristol-Myers Squibb by 217.7% in the second quarter. Edge Wealth Management LLC now owns 10,007 shares of the biopharmaceutical company’s stock valued at $452,000 after purchasing an additional 6,857 shares during the last quarter. Institutional investors and hedge funds own 77.37% of the company’s stock.

In other news, Director Robert J. Bertolini acquired 11,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was acquired at an average price of $44.72 per share, with a total value of $491,920.00. Following the completion of the transaction, the director now directly owns 11,397 shares of the company’s stock, valued at approximately $509,673.84. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.13% of the company’s stock.

BMY traded up $0.34 on Thursday, hitting $45.99. 3,794,129 shares of the stock were exchanged, compared to its average volume of 15,150,168. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $63.69. The company has a 50-day moving average of $45.29. The company has a quick ratio of 3.75, a current ratio of 3.88 and a debt-to-equity ratio of 1.51. The firm has a market capitalization of $76.06 billion, a price-to-earnings ratio of 11.55, a price-to-earnings-growth ratio of 2.30 and a beta of 0.73.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The business had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.10 billion. During the same quarter in the prior year, the business posted $1.01 earnings per share. Bristol-Myers Squibb’s revenue was up 10.0% compared to the same quarter last year. On average, equities analysts expect that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were given a dividend of $0.41 per share. The ex-dividend date was Wednesday, July 3rd. This represents a $1.64 annualized dividend and a yield of 3.57%. Bristol-Myers Squibb’s dividend payout ratio is 41.21%.

Several research firms recently commented on BMY. ValuEngine downgraded shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 2nd. Barclays upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $53.00 to $55.00 in a research note on Friday, May 3rd. BMO Capital Markets upped their price target on shares of Bristol-Myers Squibb from $62.00 to $63.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. UBS Group decreased their price target on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a research note on Thursday, June 13th. Finally, Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research note on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $55.88.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: Price Target

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.